Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETON Eton Pharmaceuticals	$13.89 -3.7%	$16.31	$3.25 ▼ $21.48	$372.50M	1.18	272,486 shs	646,959 shs
HUMA Humacyte	$2.38 +4.4%	$2.28	$1.15 ▼ $9.79	$369.19M	1.89	3.80 million shs	2.64 million shs
VIGL Vigil Neuroscience	$8.07 +0.1%	$6.72	$1.31 ▼ $8.09	$384.86M	3.34	684,755 shs	325,336 shs
ZNTL Zentalis Pharmaceuticals	$1.39 +3.7%	$1.31	$1.01 ▼ $5.44	$100.01M	1.59	1.44 million shs	646,097 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETON Eton Pharmaceuticals	-0.76%	-8.67%	+0.91%	+2.49%	+332.04%
HUMA Humacyte	-7.69%	-11.28%	-3.80%	+47.10%	-72.86%
VIGL Vigil Neuroscience	-0.12%	+0.50%	+2.54%	+433.77%	+91.90%
ZNTL Zentalis Pharmaceuticals	-1.47%	+5.51%	0.00%	+6.35%	-66.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ETON Eton Pharmaceuticals	2.101 of 5 stars	3.5	1.0	2.5	1.7	0.6
HUMA Humacyte	1.5561 of 5 stars	3.5	1.0	1.4	0.8	0.6
VIGL Vigil Neuroscience	3.7189 of 5 stars	4.0	5.0	2.2	2.5	0.6
ZNTL Zentalis Pharmaceuticals	2.4727 of 5 stars	3.3	2.0	3.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	113.58% Upside
HUMA Humacyte	3.00	Buy	$11.71	392.20% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	33.83% Upside
ZNTL Zentalis Pharmaceuticals	2.50	Moderate Buy	$8.37	501.92% Upside

Current Analyst Ratings Breakdown

Latest ZNTL, ETON, VIGL, and HUMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/28/2025	VIGL Vigil Neuroscience	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$11.00 ➝ $8.00
5/27/2025	VIGL Vigil Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$14.00 ➝ $8.00
5/23/2025	VIGL Vigil Neuroscience	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Neutral	$8.00
5/22/2025	VIGL Vigil Neuroscience	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETON Eton Pharmaceuticals	$48.33M	7.71	N/A	N/A	$0.94 per share	14.78
HUMA Humacyte	$1.57M	235.15	N/A	N/A	($0.41) per share	-5.80
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A
ZNTL Zentalis Pharmaceuticals	$67.43M	1.48	N/A	N/A	$4.73 per share	0.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETON Eton Pharmaceuticals	-$3.82M	-$0.18	N/A	27.78	N/A	-9.49%	-3.15%	-1.08%	8/4/2025 (Estimated)
HUMA Humacyte	-$148.70M	-$0.69	N/A	N/A	N/A	N/A	N/A	-73.59%	8/12/2025 (Estimated)
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	8/12/2025 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$165.84M	-$3.13	N/A	N/A	N/A	N/A	-65.48%	-51.05%	8/8/2025 (Estimated)

Latest ZNTL, ETON, VIGL, and HUMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	HUMA Humacyte	-$0.15	N/A	N/A	N/A	$0.94 million	N/A
8/12/2025	Q2 2025	VIGL Vigil Neuroscience	-$0.44	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	ZNTL Zentalis Pharmaceuticals	-$0.56	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ZNTL Zentalis Pharmaceuticals	-$0.67	-$0.67	N/A	-$0.67	N/A	N/A
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
5/13/2025	Q1 2025	HUMA Humacyte	-$0.19	-$0.10	+$0.09	$0.28	$0.46 million	$0.52 million
5/7/2025	Q1 2025	VIGL Vigil Neuroscience	-$0.53	-$0.49	+$0.04	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETON Eton Pharmaceuticals	1.23	1.97	1.43
HUMA Humacyte	0.36	3.68	3.28
VIGL Vigil Neuroscience	N/A	2.97	2.97
ZNTL Zentalis Pharmaceuticals	N/A	6.94	6.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ETON Eton Pharmaceuticals	27.86%
HUMA Humacyte	44.71%
VIGL Vigil Neuroscience	83.64%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ETON Eton Pharmaceuticals	14.89%
HUMA Humacyte	5.10%
VIGL Vigil Neuroscience	18.01%
ZNTL Zentalis Pharmaceuticals	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.83 million	Optionable
HUMA Humacyte	150	155.12 million	147.21 million	Optionable
VIGL Vigil Neuroscience	40	47.69 million	39.10 million	Not Optionable
ZNTL Zentalis Pharmaceuticals	160	71.95 million	70.59 million	Optionable

ZNTL, ETON, VIGL, and HUMA Headlines

Recent News About These Companies

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $8.37 Average Target Price from Brokerages

July 15 at 2:17 AM | americanbankingnews.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Moderate Buy" by Brokerages

July 12, 2025 | marketbeat.com

558,418 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Purchased by Peapod Lane Capital LLC

July 10, 2025 | marketbeat.com

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

Here's Why We're Watching Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

June 26, 2025 | finance.yahoo.com

Zentalis Pharmaceuticals shareholders elect three directors at annual meeting

June 20, 2025 | investing.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages

June 17, 2025 | marketbeat.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025 | globenewswire.com

First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer

May 3, 2025 | curetoday.comC

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025 | globenewswire.com

Scott Dunseth Myers Purchases 21,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock

May 1, 2025 | insidertrades.com

Zentalis shares insights on cancer research at AACR

April 29, 2025 | investing.com

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

April 28, 2025 | globenewswire.com

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

April 23, 2025 | globenewswire.com

Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 8.97%

April 10, 2025 | aaii.comA

Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 12.58%

April 2, 2025 | aaii.comA

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2025 | globenewswire.com

Stifel Nicolaus Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)

March 27, 2025 | markets.businessinsider.com

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

March 26, 2025 | globenewswire.com

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

March 25, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL, ETON, VIGL, and HUMA Company Descriptions

Eton Pharmaceuticals NASDAQ:ETON

$13.89 -0.54 (-3.74%)

Closing price 04:00 PM Eastern

Extended Trading

$13.98 +0.09 (+0.68%)

As of 05:31 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Humacyte NASDAQ:HUMA

$2.38 +0.10 (+4.39%)

Closing price 04:00 PM Eastern

Extended Trading

$2.38 0.00 (-0.21%)

As of 05:44 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Vigil Neuroscience NASDAQ:VIGL

$8.07 +0.01 (+0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$8.07 0.00 (0.00%)

As of 04:04 PM Eastern

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$1.39 +0.05 (+3.73%)

Closing price 04:00 PM Eastern

Extended Trading

$1.40 +0.01 (+0.36%)

As of 04:20 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time